EORTC-NCI-AACR SYMPOSIUM on molecular targets and cancer therapeutics
Barcelona, Spain
23-25 October 2024
News
Events
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
EORTC-NCI-AACR SYMPOSIUM on molecular targets and cancer therapeutics
Barcelona, Spain
23-25 October 2024
MODULATING DNA DAMAGE RESPONSES TO CURE CANCER
Breakpoint Therapeutics Announces Development Candidate Nomination and Start of IND-Enabling Activities of Potential Best-in-Class Polymerase Theta (Pol θ / POLQ) Inhibitor
Breakpoint Therapeutics GmbH (“Breakpoint”), a company dedicated to the discovery and development of drugs targeting the DNA Damage Response (DDR), announced today that it has nominated its first preclinical development candidate, BTX-011, an inhibitor of polymerase theta (Pol θ / POLQ) with best-in-class potential, for the treatment of solid tumours. IND-enabling activities have already commenced.
Breakpoint To Chair and Present at DDR Inhibitors Summit 2024
Breakpoint’s Managing Directors Daniel Speidel and Jon Hollick will attend the DDR Inhibitors Summit 2024 in Boston (30 January- 1 February 2024). At this international meeting, experts from industry and academia gather to share and discuss updates in the development of novel therapeutics targeting the DNA Damage response in cancer cells. Daniel Speidel will chair […]
Breakpoint To Present At Biotech Showcase
Breakpoint’s Managing Director Daniel Speidel will present a company overview during JPM at Biotech Showcase in San Francisco on January 9, 2024. Hilton Union Square 2:15 pm, Franciscan C.